ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.668,61
-1,73%
S&P 500
5.998,74
-0,38%
US Dollar vs BRL
5,9383
-0,01%
Bitcoin
95.636,12
-0,36%
Brent Oil
72,225
-0,23%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Synaptogenix Inc (SNPX)

  7. Synaptogenix Inc (SNPX) Notícias

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNPX
DataHoraFonteTítuloCódigoCompanhia
12/11/202419:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/11/202410:54Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
05/11/202408:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
28/10/202417:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
22/10/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNPXSynaptogenix Inc
10/10/202418:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SNPXSynaptogenix Inc
04/10/202417:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
23/09/202418:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SNPXSynaptogenix Inc
11/09/202410:00PR Newswire (US)Synaptogenix Announces $5.0 Million FinancingNASDAQ:SNPXSynaptogenix Inc
18/07/202410:00PR Newswire (US)Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryNASDAQ:SNPXSynaptogenix Inc
26/06/202410:00PR Newswire (US)Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
07/05/202410:00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202410:15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202410:15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202409:00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
06/02/202412:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
19/12/202311:00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
06/12/202311:00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
02/11/202310:00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202310:00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
07/09/202310:00PR Newswire (US)Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyNASDAQ:SNPXSynaptogenix Inc
19/07/202310:00PR Newswire (US)Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
13/07/202310:00PR Newswire (US)Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceNASDAQ:SNPXSynaptogenix Inc
22/06/202318:15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
15/05/202317:51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNPXSynaptogenix Inc
31/03/202317:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
21/03/202318:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SNPXSynaptogenix Inc
07/03/202311:00PR Newswire (US)Synaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesNASDAQ:SNPXSynaptogenix Inc
18/01/202318:29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SNPXSynaptogenix Inc
28/12/202218:16Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:SNPXSynaptogenix Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNPX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RCSL4
RECRUSUL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER BRASIL

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 881.64 apenas $ 352.65